Biotech China 2014

F2G Ltd Initiates Phase I Clinical Trial for FG3622

F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the initiation of a Phase I clinical study of FG3622, the company's lead antifungal drug candidate.

http://www.biotech-intelligence.com/html/html/pool_7/5f3dd068d5899ade6e060df7f03e3d6d.html



Comments

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.